Morphine and its metabolites after patient-controlled analgesia: considerations for respiratory depression

Department of Anesthesia, Stanford University, H3580, 300 Pasteur Dr, Stanford, CA 94305-5640, USA.
Journal of clinical anesthesia (Impact Factor: 1.21). 03/2011; 23(2):102-6. DOI: 10.1016/j.jclinane.2010.08.002
Source: PubMed

ABSTRACT To assess concentrations of morphine and its metabolites after patient-controlled analgesia (PCA).
Pilot pharmacokinetic study of morphine and pharmacokinetic simulation.
Post-anesthesia care room and ward of an academic teaching hospital.
10 ASA physical status I, II, and III postoperative surgical patients.
Patients received morphine via PCA by routine hospital protocols.
The population mean plasma and effect-site concentrations of morphine, morphine-6-glucuronide (M6G), and morphine-3-glucuronide (M3G) was simulated in 4 patient group scenarios: morphine PCA used alone, morphine PCA used with continuous background morphine infusion of 0.5 mg/hr, morphine PCA used with continuous background morphine infusion of 1.0 mg/hr, and morphine PCA used with continuous background morphine infusion of 2.0 mg/hr.
The 4 groups exhibited simulated peak morphine, M6G, and M3G effect-site concentrations at 8 to 24 hours post-infusion. The highest peak morphine, M6G, and M3G effect-site concentrations decreased in the following order by group: 2.0 mg/hr morphine infusion + PCA group, 1.0 mg/hr morphine infusion + PCA group, and 0.5. mg/hr morphine infusion + PCA group.
Patients receiving morphine PCA should be monitored closely from 8 to 24 hours postoperatively. Morphine PCA given with background infusion rates up to 1.0 mg/hr does not offer distinct pharmacokinetic advantages over morphine PCA alone. Morphine PCA with background infusion rate of 2.0 mg/hr is associated with the greatest risk of respiratory depression.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Treating chronic pain in the context of opioid misuse can be very challenging. This paper explores the epidemiology and potential treatments for chronic pain and opioid misuse and identifies educational and regulation changes that may reduce diversion of opioid analgesics. We cover the epidemiology of chronic pain and aberrant opioid behaviors, psychosocial influences on pain, pharmacological treatments, psychological treatments, and social treatments, as well as educational and regulatory efforts being made to reduce the diversion of prescription opioids. There are a number of ongoing challenges in treating chronic pain and opioid misuse, and more research is needed to provide strong, integrated, and empirically validated treatments to reduce opioid misuse in the context of chronic pain.
    08/2011; 2:145-162. DOI:10.2147/SAR.S12944
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This analysis was done to investigate the optimal regimen for fentanyl-based intravenous patient-controlled analgesia (IV-PCA) by finding a safe and effective background infusion rate and assessing the effect of adding adjuvant drugs to the PCA regimen. Background infusion rate of fentanyl, type of adjuvant analgesic and/or antiemetic that was added to the IV-PCA, and patients that required rescue analgesics and/or antiemetics were retrospectively reviewed in 1827 patients who underwent laparoscopic abdominal surgery at a single tertiary hospital. Upon multivariate analysis, lower background infusion rates, younger age, and IV-PCA without adjuvant analgesics were identified as independent risk factors of rescue analgesic administration. Higher background infusion rates, female gender, and IV-PCA without additional 5HT₃ receptor blockers were identified as risk factors of rescue antiemetics administration. A background infusion rate of 0.38 μg/kg/hr [area under the curve (AUC) 0.638] or lower required rescue analgesics in general, whereas, addition of adjuvant analgesics decreased the rate to 0.37 μg/kg/hr (AUC 0.712) or lower. A background infusion rate of 0.36 μg/kg/hr (AUC 0.638) or higher was found to require rescue antiemetics in general, whereas, mixing antiemetics with IV-PCA increased the rate to 0.37 μg/kg/hr (AUC 0.651) or higher. Background infusion rates of fentanyl between 0.12 and 0.67 μg/kg/hr may safely be used without any serious side effects for IV-PCA. In order to approach the most reasonable background infusion rate for effective analgesia without increasing postoperative nausea and vomiting, adding an adjuvant analgesic and an antiemetic should always be considered.
    Yonsei medical journal 05/2014; 55(3):800-6. DOI:10.3349/ymj.2014.55.3.800 · 1.26 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The effect of opioids on tumour growth and metastasis has been debated for years, with recent emphasis on the possibility that they might influence the rate of disease-free survival after tumour resection when employed in the perioperative pain management of cancer surgery patients. The literature presents conflicting and inconclusive in vitro and in vivo data about the potential effect of opioids, and especially morphine, on tumour growth and metastasis. In order to inform clinical practice, appropriate animal models should be employed to test whether opioids alter the course of tumour growth and metastasis. We review the literature on animal-based studies testing the effect of morphine on cancer so far, and analyse differences between the models employed that may explain the discrepancies in published results, shed light on the role of opioids in cancer, and help define ideal preclinical models to provide a definitive answer.
    British Journal of Pharmacology 01/2014; DOI:10.1111/bph.12589 · 4.99 Impact Factor


Available from
Feb 11, 2015